₹268.90
−3.20%NSE close, 16 Nov 2026
+41.77%
Suven Life Sciences is a small cap company in the Healthcare sector, listed on NSE under the symbol SUVEN. At ₹268.90 a share, the market values the whole company at ₹7,598 crore.
In FY26, it reported sales of ₹7 crore and a net loss of ₹276 crore, an operating margin of -4,001.4%. Over the last three years, sales fell 19.3% a year.
The market values the company at 16.75 times its book value; its return on equity is -84.2% and it has almost no borrowings.
Promoters hold 65.47% of the shares. Foreign institutions hold 0.46%, and domestic institutions, mutual funds among them, 2.17%.
Over the past year the share price has risen 39.5%, and it is 33.3% below its 52-week high.
Companies of a similar size in the same sector include Blue Jet Healthcare, Procter & Gamble Health, Strides Pharma Science and Aarti Pharmalabs.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% |
A revised press release dated November 16, 2026, titled "Please find enclosed the Revised News Release of our Company
Please find enclosed News Release of our Company
Suven Life Sciences to Present Seven Scientific Posters Highlighting Its CNS Drug Discovery and Development Pipeline at Neuroscience 2026 (SfN), Washington DC, USA
The financial results for the period ended September 30, 2026.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 2.5 | 2.4 | 1.0 | 2.6 | 1.6 | 1.5 | 1.9 | 0.9 | 2.8 | 1.5 | 3.6 | 1.2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 48.6 | 32.7 | 31.6 | 54.8 | 40.8 | 45.3 | 52.6 | 80.7 | 106 | 52.2 | 136 | 112 |
| Operating profit | −46.2 | −30.3 | −30.5 | −52.2 | −39.2 | −43.8 | −50.8 | −79.8 | −103 | −50.6 | −133 | −111 |
| Operating margin | -1,885.3% | -1,267.4% | -3,023.8% | -2,031.5% | -2,435.4% | -2,981.0% | -2,713.9% | -8,670.7% | -3,677.9% | -3,330.9% | -3,711.5% | -9,243.3% |
| Other income | 6.1 | 4.3 | 4.0 | 4.0 | 1.6 | 1.2 | 0.6 | 3.8 | 2.8 | 6.8 | 7.5 | 6.7 |
| Interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0.2 | 0.5 | 0.5 |
| Depreciation | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.3 | 1.4 | 1.6 | 2.2 | 2.3 |
| Profit before tax | −41.8 | −27.5 | −28.0 | −49.6 | −39.1 | −43.9 | −51.5 | −77.3 | −102 | −45.6 | −128 | −107 |
| Tax | 0 | −1.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | −41.8 | −26.5 | −28.0 | −49.6 | −39.1 | −43.9 | −51.5 | −77.3 | −102 | −45.6 | −128 | −107 |
| EPS (₹) | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 | -4.84 | -3.77 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 664 | 14.4 | 13.5 | 11.8 | 13.5 | 11.7 | 6.7 | 7.1 |
| Expenses | 503 | 130 | 93.6 | 134 | 139 | 140 | 172 | 292 |
| Operating profit | 160 | −116 | −80.1 | −122 | −126 | −128 | −166 | −285 |
| Operating margin | 24.2% | -803.1% | -594.0% | -1,033.7% | -929.8% | -1,094.0% | -2,489.0% | -4,001.4% |
| Other income | 24.2 | 14.0 | 7.8 | 5.3 | 8.5 | 21.1 | 10.9 | 13.9 |
| Interest | 3.8 | 0.6 | 0.8 | 0.5 | 0.3 | 0.2 | 0.1 | 0.2 |
| Depreciation | 22.1 | 4.2 | 4.4 | 4.4 | 6.5 | 6.5 | 5.8 | 5.6 |
| Profit before tax | 159 | −106 | −77.5 | −122 | −118 | −106 | −161 | −276 |
| Tax | 71.8 | −12.2 | −5.3 | 0 | 0 | −1.0 | 0 | 0 |
| Net profit | 86.9 | −94.2 | −72.2 | −122 | −118 | −105 | −161 | −276 |
| EPS (₹) | 6.83 | -2.01 | -5.67 | -9.57 | -6.78 | -4.82 | -7.37 | -12.13 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | −128 | −154 | −302 | −222 |
| From investing | −22.2 | 155 | −462 | 145 |
| From financing | 146 | −0.8 | 757 | 92.6 |
| Spent on fixed assets | −19.8 | −37.3 | −5.1 | −45.9 |
| Free cash flow | −147 | −191 | −307 | −268 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 13.1% | -653.9% | -535.2% | -1,030.4% | -873.5% | -898.0% | -2,413.5% | -3,886.6% |
| Operating margin | 24.2% | -803.1% | -594.0% | -1,033.7% | -929.8% | -1,094.0% | -2,489.0% | -4,001.4% |
| Return on equity | – | – | – | – | -31.5% | -38.9% | -146.1% | -46.7% |
| Return on capital employed | – | – | – | – | -31.4% | -39.2% | -146.1% | -46.7% |
| Return on assets | – | – | – | – | -30.4% | -36.9% | -118.9% | -44.3% |
| Debt to equity | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 43.10 | -192.50 | -93.50 | -229.20 | -421.40 | -661.90 | -3,213.80 | -1,726.10 |
| Debt to assets | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | – | – | – | – | 22.60 | 18.98 | 3.21 | 17.69 |
| Quick ratio | – | – | – | – | 22.60 | 18.93 | 3.20 | 17.69 |
| Cash ratio | – | – | – | – | 3.33 | 1.10 | 0.64 | 0.27 |
| Asset turnover | – | – | – | – | 0.03 | 0.04 | 0.05 | 0.01 |
| Fixed asset turnover | – | – | – | – | 0.38 | 0.43 | 0.11 | 0.13 |
| Receivables turnover | – | – | – | – | 16.70 | 9.10 | 5.00 | 4.70 |
| Effective tax rate | 45.2% | – | – | – | – | – | – | – |
| +45.90% |
| +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
|---|
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
|---|
Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)
Proceedings of Annual General Meeting held on August 25, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
Monitoring Agency Report for the quarter ended June 30, 2026
The financial results for the period ended Jun 30, 2026.
Letter to Shareholders regarding Annual Report 2025-26
Business Responsibility and Sustainability Report for F.Y 2025-26
Notice of Annual General Meeting to be held on August 25, 2026
Schedule of meet
Suven Life Sciences to Present Five Scientific Posters, Including Global Phase-3 Masupirdine Study Updates and Usmarapride Phase-2 clinical development program at Alzheimer's Association International Conference (A Global Forum to Advance Dementia Science) AAIC-2026 during…
Revised outcome of Board Meeting - Incorporation of Wholly owned Subsidiary (WOS) in Singapore